Drug intelligence / Profile preview

orlistat + metformin

Development stage
Unknown
Lead developer
Sheffield Teaching Hospitals
Modality
Small Molecules
Administration
Oral
01

Overview

This entry refers to a clinical trial comparison between **orlistat** and **metformin** conducted by the Sheffield Teaching Hospitals NHS Foundation Trust. Orlistat is a gastrointestinal lipase inhibitor used for weight management by preventing the absorption of dietary fats. Metformin is a biguanide antihyperglycemic agent that improves insulin sensitivity and is frequently used off-label to treat polycystic ovary syndrome (PCOS) and related anovulation. The study specifically investigates the efficacy of these two agents in inducing weight loss and restoring ovulation in obese women who are experiencing anovulatory infertility. While both drugs are well-established in their respective primary indications, this trial (NCT00406133) aimed to determine the optimum management strategy for reproductive dysfunction in the context of obesity.

Brand names
XenicalAlliGlucophageFortametGlumetzaRiomet
Other names
Orlistat Vs MetforminMetformin Versus Orlistat
02

Targets

LIPF (Gastric lipase)PNLIP (Pancreatic triacylglycerol lipase)AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)

Beyond the preview

Go deeper on orlistat + metformin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on orlistat + metformin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call